Treatment of osteoporosis: all the questions we still cannot answer

The American Journal of Medicine
Michel Laroche

Abstract

Many questions remain with regard to the treatment of osteoporosis. The increase in bone mineral density due to bisphosphonates accounts for only a quarter of their antifracture action. The studies of bone mineral density equivalences that have validated certain modes of administration are therefore not relevant. No comparative study on the same patient cohort has been carried out, and the inclusion criteria of the pilot studies on the drugs currently available are all different. This makes any comparison impossible, and thus, the choice of treatment is subjective. Certain combinations (antiresorptive drugs and anabolic agents) are logical, but no major study is available to validate them. Drugs with a long latency period could interfere with later treatments or allow therapeutic windows, but the data in the literature in support of these hypotheses are scarce. The osteoporotic patient will require treatment for 10 to 30 years, depending on the age at diagnosis, but the available data on the efficacy and nontoxicity of the drugs are based on studies of a duration of only 3 or 5 years.

References

Apr 17, 1979·Calcified Tissue International·H Fleisch, R Felix
Nov 30, 2000·The Journal of Clinical Endocrinology and Metabolism·D M BlackUNKNOWN Fracture Intervention Trial
Jun 22, 2002·Lancet·Pierre D Delmas
Jan 30, 2004·The New England Journal of Medicine·Pierre J MeunierJean-Yves Reginster
Apr 8, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Bruce EttingerImre Pavo
Jul 3, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Charles H ChesnutUNKNOWN Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)
Jul 3, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Kristine E EnsrudUNKNOWN Fracture Intervention Trial Long-Term Extension Research Group
Sep 30, 2004·Calcified Tissue International·D D MellströmA A Chines
Oct 4, 2005·Current Medical Research and Opinion·Silvana MartinoJohn L Mershon
Nov 8, 2005·The American Journal of Medicine·Clifford J Rosen, Sue A Brown
Aug 31, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Glen M Blake, Ignac Fogelman

❮ Previous
Next ❯

Citations

Apr 13, 2010·Rheumatology International·Joong Kyong AhnEun-Mi Koh
Jul 15, 2011·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Jimmy D AleleRosalind Ramsey-Goldman
Jun 3, 2010·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ginelle A SchmidtKevin G Moores
Jun 11, 2009·Journal of Endocrinological Investigation·Y-H BuA-G Tang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.